Known targets — ChEMBL curated mechanism
CDK1CDK10CDK11BCDK12CDK13CDK14CDK15CDK16CDK17CDK18CDK19CDK2CDK20CDK3CDK4CDK5CDK6CDK7CDK8CDK9
The experimentally established mechanism targets of Pha-793887. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 known ✓ | P24941 | 20/20 | 1.00 |
| ▸ | CDK1 known ✓ | P06493 | 1/20 | 1.00 |
| ▸ | CDK4 known ✓ | P11802 | 1/20 | 1.00 |
| ▸ | CDK7 known ✓ | P50613 | 1/20 | 1.00 |
| ▸ | CDK9 known ✓ | P50750 | 1/20 | 1.00 |
| ▸ | CDK3 known ✓ | Q00526 | 1/20 | 1.00 |
| ▸ | CDK5 known ✓ | Q00535 | 1/20 | 1.00 |
| ▸ | CDK16 known ✓ | Q00536 | 1/20 | 1.00 |
| ▸ | CDK13 known ✓ | Q14004 | 1/20 | 1.00 |
| ▸ | CDK12 known ✓ | Q9NYV4 | 1/20 | 1.00 |
| ▸ | CCNA2 | P20248 | 20/20 | 1.00 |
| ▸ | CCNA1 | P78396 | 20/20 | 1.00 |
| ▸ | CCNT1 | O60563 | 1/20 | 1.00 |
| ▸ | ULK1 | O75385 | 1/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 1/20 | 1.00 |
| ▸ | PAK4 | O96013 | 1/20 | 1.00 |
| ▸ | CCNB1 | P14635 | 1/20 | 1.00 |
| ▸ | PHKG2 | P15735 | 1/20 | 1.00 |
| ▸ | ERCC2 | P18074 | 1/20 | 1.00 |
| ▸ | CCND1 | P24385 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pha-793887 SCHEMBL31069494 | 0.99 | CCNA2 (0.98) | CCNA2CDK2CCNA1CCNT1ULK1 | |
| SCHEMBL24669470 | 0.88 | CCNA2 (0.82) | CCNA2CDK2CCNA1CCNT1ULK1 | |
| SCHEMBL22272113 | 0.83 | CCNA2 (0.78) | CCNA2CDK2CCNA1CCNT1ULK1 | |
| SCHEMBL25008205 | 0.80 | CCNA2 (0.66) | CCNA2CDK2CCNA1CCNT1ULK1 | |
| SCHEMBL24513389 | 0.79 | CCNA2 (0.66) | CCNA2CDK2CCNA1CCNT1ULK1 | |
| SCHEMBL28427761 | 0.76 | CCNA2 (0.61) | CCNA2CDK2CCNA1CCNT1ULK1 | |
| SCHEMBL24669016 | 0.75 | CCNA2 (0.59) | CCNA2CDK2CCNA1CCNT1ULK1 | |
| SCHEMBL28427763 | 0.74 | CCNA2 (0.59) | CCNA2CDK2CCNA1CCNT1ULK1 | |
| SCHEMBL22355618 | 0.73 | CCNA2 (0.54) | CCNA2CDK2CCNA1CCNT1ULK1 | |
| SCHEMBL15095340 | 0.72 | CDK2 (0.56) | CCNA2CDK2CCNA1CCNT1ULK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 368 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590966-B2 | Method for treating cancer | THE CHILDREN'S MEDICAL CENTER CORPORATION | 2026-03-31 | — | — | US | claimed |
| EP-4698175-A1 | LYSINE ACETYLTRANSFERASE 6A (KAT6A) INHIBITOR, COMBINATIONS AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2026-02-25 | — | — | EP | claimed |
| EP-3820461-B1 | USE OF ASPARAGINASE IN COMBINATION WITH GSK3A INHIBITION FOR TREATING CANCER | CHILDRENS MEDICAL CT CORP (US) | 2026-01-07 | — | — | EP | claimed |
| US-20250332145-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF CANCER | Piramal Enterprises Limited (IN) | 2025-10-30 | — | — | US | claimed |
| EP-4640238-A1 | THERAPEUTIC AGENT FOR PULMONARY DISEASE, HEPATIC DISEASE OR RENAL DISEASE, WHICH CONTAINS PGAM-CHK1 BINDING INHIBITOR | Kyoto University (JP) | 2025-10-29 | — | — | EP | claimed |
| US-12383529-B2 | Pharmaceutical combination for the treatment of cancer | Piramal Enterprises Limited (IN) | 2025-08-12 | — | — | US | claimed |
| WO-2025151443-A1 | ENDOXIFEN FOR TREATMENT OF RARE CANCERS | ATOSSA THERAPEUTICS, INC. (US) | 2025-07-17 | — | — | WO | claimed |
| EP-4529926-A1 | METHOD FOR TREATING CANCER BY COMBINING ALKYLATING AGENT PRODRUG AND CELL CYCLE INHIBITOR | Ascentawits Pharmaceuticals, Ltd. (CN) | 2025-04-02 | — | — | EP | claimed |
| WO-2025051337-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING ORAL CANCER | Afyx Development A/S (DK) | 2025-03-13 | — | — | WO | claimed |
| US-20250011425-A1 | COMPOSITIONS AND METHODS FOR IMPROVED T CELLS | UNIV TEMPLE (US) | 2025-01-09 | — | — | US | claimed |
| US-20220169735-A1 | METHODS OF SENSITIZING CANCER TO IMMUNOTHERAPY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-06-02 | — | — | US | claimed |
| US-20220168273-A1 | Pharmaceutical Combination for the Treatment of Cancer | Piramal Enterprises Limited (IN) | 2022-06-02 | — | — | US | claimed |
| EP-3976195-A1 | METHODS FOR TREATING SMALL CELL NEUROENDOCRINE AND RELATED CANCERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-04-06 | — | — | EP | claimed |
| WO-2022051616-A1 | CDK TARGETED HETEROBIFUNCTIONAL SMALL MOLECULE PROTEOLYSIS TARGETING CHIMERAS | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2022-03-10 | — | — | WO | claimed |
| US-11234963-B2 | Pharmaceutical combination for the treatment of cancer | Piramal Enterprises Limited (IN) | 2022-02-01 | — | — | US | claimed |
| CN-105143445-B | Maturation of hepatocyte-like cells derived from human pluripotent stem cells | 宝生物欧洲公司 | 2020-07-07 | — | — | CN | claimed |
| EP-2925859-A1 | MATURATION OF HEPATOCYTE-LIKE CELLS DERIVED FROM HUMAN PLURIPOTENT STEM CELLS | Takara Bio Europe AB (SE) | 2015-10-07 | — | — | EP | claimed |
| WO-2014083132-A1 | MATURATION OF HEPATOCYTE-LIKE CELLS DERIVED FROM HUMAN PLURIPOTENT STEM CELLS | CELLECTIS SA (FR) | 2014-06-05 | — | — | WO | claimed |
| US-7407971-B2 | Substituted pyrrolo-pyrazole derivatives as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2008-08-05 | — | — | US | claimed |
| US-20070004705-A1 | Substituted pyrrolo-pyrazole derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2007-01-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004705-A1 | Substituted pyrrolo-pyrazole derivatives as kinase inhibitors | CCNI, CDK1, CDK2 | CDK2 3/4885CDK1 2/4885CDK4 8/4885 |
| US-12590966-B2 | Method for treating cancer | GSK3B, GSK3A, GSKIP | CDK2 542/4885CDK1 238/4885CDK4 1419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.